

	All			Tumor PD-L1 ≥ 1%			Tumor PD-L1 < 1%		
	NIVO+IPI (N = 74)	SUN (N = 65)	P value	NIVO+IPI (N = 36)	SUN (N = 33)	P value	NIVO+IPI (N = 35)	SUN (N = 29)	P value
mOS (95% CI), months	49 (25–NE)	14 (9–23)	–	NR (30–NE)	21 (9–41)	–	40 (19–NE)	14 (6–20)	–
OS HR (95% CI)	0.46 (0.29–0.71)		0.0004	0.40 (0.19–0.84)		0.0143	0.42 (0.22–0.78)		0.0049
OS probability ≥ 5 years (95% CI), %	47 (35–58)	21 (12–32)	–	55 (37–70)	29 (15–45)	–	44 (27–60)	14 (4–29)	–
mPFS (95% CI), months	26 (7–NE)	5 (4–7)	–	NR (9–NE)	6 (3–7)	–	9 (3–47)	5 (4–17)	–
PFS HR (95% CI)	0.50 (0.32–0.80)		0.0036	0.29 (0.14–0.57)		0.0002	0.65 (0.34–1.24)		0.1894
PFS probability ≥ 5 years (95% CI), %	46 (33–58)	12 (3–27)	–	60 (41–75)	14 (4–31)	–	33 (17–49)	NR ^a	–
ORR (95% CI), %	61 (49–72)	23 (14–35)	<0.0001	69 (52–84)	24 (11–42)	–	54 (37–71)	21 (8–40)	–
Complete response, %	23	6	–	25	9	–	23	3	–
Partial response, %	38	17	–	44	15	–	31	17	–

^aMinimum follow-up NR; 0 patients at risk at 5 years.

CI, confidence interval; HR, hazard ratio; m, median; NE, not estimable; NR, not reached; PD-L1, programmed death ligand 1.